UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the
month of March 2026
Commission
File Number 001-15170
GSK plc
(Translation
of registrant's name into English)
79 New Oxford Street, London, WC1A 1DG
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F . . . .X. . . . Form 40-F . . . . . . . .
Issued: 25 March 2026, London UK
GSK plc Publication
of Notice of Annual General Meeting 2026
The Company has today published on its website (www.gsk.com/en-gb/investors/shareholder-information/annual-general-meeting/) the
Notice of Annual General Meeting ('AGM') 2026 (the '2026 AGM
Notice'), which will be distributed to shareholders
shortly.
The Company's AGM will be held on Wednesday 6 May 2026 at 2.30pm at
the London Marriott Hotel Grosvenor Square, Grosvenor Square,
London, W1K 6JP and will also be broadcast live for shareholders to
join electronically. Full details of how to join the meeting
either in person or electronically are contained in the 2026 AGM
Notice and AGM Guide.
In compliance with Listing Rule 6.4.1R of the UK Financial Conduct
Authority's ('FCA') Listing Rules, the following documents will be
submitted to the FCA and will, in due course, be available for
inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism:
● 2026 AGM Notice
● Proxy Form for the AGM
●
The Company's Articles of Association marked up to show
proposed changes
V A Whyte
Company Secretary
25 March 2026
About GSK
GSK is a global biopharma company with a purpose to unite science,
technology, and talent to get ahead of disease together. Find out
more at gsk.com.
Cautionary statement regarding forward-looking
statements
GSK cautions investors that any forward-looking statements or
projections made by GSK, including those made in this announcement,
are subject to risks and uncertainties that may cause actual
results to differ materially from those projected. Such factors
include, but are not limited to, those described under Item 3.D
"Risk factors" in GSK's Annual Report on Form 20-F for
2025.
Registered in England & Wales:
No.
3888792
Registered Office:
79
New Oxford Street
London
WC1A
1DG
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
|
GSK plc
|
|
|
(Registrant)
|
|
|
|
|
Date: March
25, 2026
|
|
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
|
|
Victoria Whyte
|
|
|
Authorised
Signatory for and on
|
|
|
behalf
of GSK plc
|